Ceftazidime -avibactam + Meropenem + Metronidazole
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infections
Conditions
Complicated Intra-abdominal Infections
Trial Timeline
Aug 1, 2015 → Jun 1, 2017
NCT ID
NCT02475733About Ceftazidime -avibactam + Meropenem + Metronidazole
Ceftazidime -avibactam + Meropenem + Metronidazole is a phase 2 stage product being developed by Pfizer for Complicated Intra-abdominal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT02475733. Target conditions include Complicated Intra-abdominal Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02475733 | Phase 2 | Completed |
Competing Products
20 competing products in Complicated Intra-abdominal Infections